This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernandez, S.
Right arrow Articles by Graybill, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernandez, S.
Right arrow Articles by Graybill, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2004, p. 1382-1383, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1382-1383.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis

Steve Hernandez,1* José L. López-Ribot,1,2 Laura K. Najvar,1 Dora I. McCarthy,3 Rosie Bocanegra,1 and John R. Graybill1

Department of Medicine, Division Infectious Diseases (7881),1 Department of Microbiology,2 Department of Pathology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229-39003

Received 13 May 2003/ Returned for modification 4 October 2003/ Accepted 9 December 2003


arrow
ABSTRACT
 
A patient with azole-refractory thrush-esophagitis responded initially to caspofungin, but the treatment eventually failed. In a murine model, caspofungin was effective against two early isolates for which the MICs of caspofungin were low, but it was less effective against a late isolate for which the MIC of caspofungin was greater. We concluded that there is a correlation between in vivo failure and rising in vitro caspofungin MICs.


arrow
TEXT
 
The National Committee for Clinical Laboratory Standards (NCCLS) has generated standardized in vitro testing methods for triazoles (9). Fluconazole is currently the drug of choice for treatment of mucosal and systemic Candida infection (13). However, isolates of Candida albicans and C. glabrata for which the fluconazole MICs are >=64 µg/ml have been associated with clinical failure of fluconazole therapy (14, 15). However, it is unclear whether results of in vitro testing can be generalized from triazoles to other antifungals such as the echinocandins. These compounds inhibit fungal cell wall synthesis by blocking formation of 1,3-ß-D-glucans (2, 5; K. Bartizal, M. Motyl, P. Hicks, C. Sable, M. DiNubile, and N. Kartsonis, Abstr. 42nd Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1240, 2002). Caspofungin, a licensed echinocandin, acts rapidly against Candida spp. and is considered by some to be fungicidal in vitro (3). The MIC of caspofungin is very low (<=1 µg/ml) for virtually all C. albicans isolates. Caspofungin is as effective as fluconazole in the treatment of thrush and esophagitis (1). Patients with esophagitis caused by fluconazole-resistant C. albicans isolates have also responded to caspofungin (C. Kutler, B. Koll, B. Raucher, and B. Saltznab, 40th Annu. Meet. IDSA, abstr. 350, 2002).

In contrast to C. albicans, caspofungin MICs of >=4 µg/ml have been reported for C. parapsilosis (8). In a large in vitro survey, Pfaller et al. found that only 60% of 420 C. parapsilosis isolates showed susceptibility to caspofungin at 1 µg/ml versus >96% of more than 3,000 isolates of the other species tested, including 99% of 2,453 C. albicans isolates (11). However, when caspofungin was used for the treatment of patients with candidemia, those with C. parapsilosis fungemia (14 of 20) responded as well as those with C. albicans and other species (13 of 20) (8). Therefore, the correlation of in vitro susceptibility and clinical response, at least for C. parapsilosis, does not seem as close for caspofungin as for fluconazole (4, 6, 12). Additionally, pharmacokinetic considerations such as drug access to sites of infection, distribution in tissue, or clearance may contribute to clinical failure. Thus, it is not clear what role MIC testing has in the prediction of the success or failure of caspofungin therapy. The patient reported in this study allowed us to examine the relationship of a rising in vitro caspofungin MIC and clinical outcome of C. albicans esophagitis.

A patient with AIDS (CD4 count of 32 cells/ml of blood) presented with thrush and esophagitis on day 1. Previous therapy with fluconazole at 200 mg twice per day (BID) for 24 weeks and amphotericin B lipid complex at 200 mg BID for 1 week had failed. Esophagoscopy confirmed grade 1 Candida esophagitis. Following cultures, he was treated with a loading dose of 70 mg of caspofungin, followed by 50 mg/day (intravenously) for 28 days. His thrush improved at day 6 and was cleared at day 13. His esophagitis responded symptomatically, and later esophagoscopy at 25 days of therapy showed grade 0. Therapy was stopped at 28 days, and the thrush and symptoms of esophagitis returned 22 days later. Caspofungin was reinitiated. The patient improved, but his dense confluent plaques did not resolve completely. The therapy eventually failed, at which time caspofungin was combined with amphotericin B lipid complex at 2 mg/kg. There was no significant improvement on this regimen, and the therapy was declared a failure after 2 months.

During this period, C. albicans isolates were recovered from the oral cavity of the patient. Isolate 1 was obtained on day 1, which was prior to caspofungin administration. Isolate 2 was obtained on day 511 after isolate 1. This is 50 days after the first course of successful treatment began. Isolate 3 was obtained on day 553 after isolate 1. This is after clinical failure. Strain identity was investigated by karyotyping, restriction fragment length polymorphism, fingerprinting analysis with moderately repetitive probe Ca3, and sequencing of ERG11 genes as described previously by our group (7, 10). DNA typing and microsatellite locus sequencing methods cannot definitively guarantee that strain 3 arose from strain 2. However, all of these methods strongly suggested that these three isolates were isogenic, and thus the results strongly support the development of resistance in the same strain.

By the NCCLS method with RPMI 1640 medium, the fluconazole MIC for all three isolates at 48 h of incubation was >64 µg/ml. The caspofungin MICs for isolates 1 and 2 at 48 h were 0.25 µg/ml in RPMI 1640 medium and 0.125 µg/ml in antibiotic medium 3 (AM3). The caspofungin MIC of isolate 3 was >64 µg/ml in RPMI 1640 medium and 0.5 µg/ml in AM3 at 48 h. Thus, the results of susceptibility testing indicated rising MICs due to caspofungin treatment in the same infecting C. albicans strain. The rise in the MIC was much greater in RPMI medium than in AM3. The NCCLS has, in general, used RPMI 1640 medium as the test medium, although AM3 is preferred for amphotericin B MIC testing. RPMI medium shows trailing with some Candida strains, although this was not a problem with our isolates. No method has been adopted as a standard for caspofungin MIC testing.

For in vivo studies, the C. albicans isolates were cultured in brain heart infusion broth at 37°C for 24 h before infection. ICR mice were inoculated intravenously with a 0.2-ml volume. The inoculum of viable organisms was determined by serial dilution of quantitative cultures. Therapy began 1 day after infection and continued through day 7. Caspofungin was given intraperitoneally at 0.0625, 0.125, 0.25, 0.5, and 1 mg/kg/day. Fluconazole was given orally by gavage at 5 mg/kg BID. Controls received sterile water orally by gavage. For any mice succumbing before day 8, the kidneys were removed, weighed, and homogenized for quantitative determination of fungal counts in the tissue. All surviving mice were terminated on day 8, and organs were removed for determination of fungal counts in tissues. The Mann-Whitney test, (with P <= 0.05 necessary for significance) was used to compare differences in tissue burdens between the treatment groups and controls. The results, shown in Table 1, indicate that treatment with fluconazole at 5 mg/kg BID did not reduce the counts of any isolate in kidney tissue. Treatment with caspofungin at 0.0625 to 1 mg/kg significantly reduced the counts of isolate 1 in kidney tissue. Treatment with doses of 0.125 to 1 mg/kg reduced the counts of isolate 2 in kidney tissue. However, caspofungin at 0.0625 mg/kg did not reduce counts (P >= 0.05). Caspofungin reduced the counts of isolate 3 in kidney tissue only at 1 mg/kg, while doses ranging from 0.5 to 0.625 mg/kg failed to do so.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Fungal burdens in kidneys of mice infected with C. albicans

In summary, an elevated in vitro MIC in both RPMI medium and AM3 correlated with a clinical outcome of reduced susceptibility to caspofungin in this study of one patient, as well as in a mouse model of disseminated candidiasis.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: The University of Texas Health Science Center at San Antonio, Department of Medicine, Division of Infectious Diseases (7881), 7703 Floyd Curl Dr., San Antonio, TX 78229-3900. Phone: (210) 567-0990. Fax: (210) 567-0962. E-mail: Hernandezs{at}uthscsa.edu. Back


arrow
REFERENCES
 
    1
  1. Arathoon, E. G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46:451-457.[Abstract/Free Full Text]
    2. 2
  2. Douglas, C. M., J. A. D'ippolito, G. J. Shei, M. Meinz, J. Onishi, J. A. Marrinan, W. Li, G. K. Abruzzo, A. Flattery, K. Bartizal, A. Mitchell, and M. B. Kurtz. 1997. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-ß-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. 41:2471-2479.[Abstract]
    3. 3
  3. Ernst, E. J., M. E. Klepser, and M. Pfaller. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:1108-1111.[Abstract/Free Full Text]
    4. 4
  4. Graybill, J. R. 1995. Antifungal drugs and resistance. Adv. Exp. Med. Biol. 390:217-234.[Medline]
    5. 5
  5. Hector, R. F. 1993. Compounds active against cell walls of medically important fungi. Clin. Microbiol. Rev. 6:1-21.[Abstract/Free Full Text]
    6. 6
  6. Hitchcock, C. A., G. W. Pye, P. F. Troke, E. M. Johnson, and D. W. Warnock. 1993. Fluconazole resistance in Candida glabrata. Antimicrob. Agents Chemother. 37:1962-1965.[Abstract/Free Full Text]
    7. 7
  7. Lopez-Ribot, J. L., R. K. McAtee, L. N. Lee, W. R. Kirkpatrick, T. C. White, D. Sanglard, and T. F. Patterson. 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 42:2932-2937.[Abstract/Free Full Text]
    8. 8
  8. Mora-Duarte, J., R. Betts, C. Rotstein, A. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.[Abstract/Free Full Text]
    9. 9
  9. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    10. 10
  10. Perea, S., J. L. López-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. Santillán, M. Martínez, D. Calabrese, D. Sanglard, and T. F. Patterson. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2676-2684.[Abstract/Free Full Text]
    11. 11
  11. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.[Abstract/Free Full Text]
    12. 12
  12. Quereda, C., A. M. Polanco, C. Giner, A. Sanchez-Sousa, E. Pereira, E. Navas, J. Fortun, A. Guerrero, and F. Baquero. 1996. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients. Eur. J. Clin. Microbiol. Infect. Dis. 15:30-37.[CrossRef][Medline]
    13. 13
  13. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. D. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.[Abstract/Free Full Text]
    14. 14
  14. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.[Medline]
    15. 15
  15. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.[Abstract/Free Full Text]

Antimicrobial Agents and Chemotherapy, April 2004, p. 1382-1383, Vol. 48, No. 4
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.4.1382-1383.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Arendrup, M. C., Garcia-Effron, G., Buzina, W., Mortensen, K. L., Reiter, N., Lundin, C., Jensen, H. E., Lass-Florl, C., Perlin, D. S., Bruun, B. (2009). Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing. Antimicrob. Agents Chemother. 53: 1185-1193 [Abstract] [Full Text]  
  • Wiederhold, N. P., Grabinski, J. L., Garcia-Effron, G., Perlin, D. S., Lee, S. A. (2008). Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans. Antimicrob. Agents Chemother. 52: 4145-4148 [Abstract] [Full Text]  
  • Thompson, G. R. III, Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S. II, Patterson, T. F. (2008). Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection. Antimicrob. Agents Chemother. 52: 3783-3785 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., Dannaoui, E. (2008). Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52: 3092-3098 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., Sheehan, D. J., Walsh, T. J. (2008). Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints. J. Clin. Microbiol. 46: 2620-2629 [Abstract] [Full Text]  
  • Desnos-Ollivier, M., Dromer, F., Dannaoui, E. (2008). Detection of Caspofungin Resistance in Candida spp. by Etest. J. Clin. Microbiol. 46: 2389-2392 [Abstract] [Full Text]  
  • Pfaller, M. A., Chaturvedi, V., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., Ramani, R. (2008). Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin. J. Clin. Microbiol. 46: 2155-2159 [Abstract] [Full Text]  
  • Brown, S. D., Traczewski, M. M. (2008). Caspofungin Disk Diffusion Breakpoints and Quality Control. J. Clin. Microbiol. 46: 1927-1929 [Abstract] [Full Text]  
  • Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., Hou, J. (2008). In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 539-550 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2008). In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J. Clin. Microbiol. 46: 150-156 [Abstract] [Full Text]  
  • Baixench, M.-T., Aoun, N., Desnos-Ollivier, M., Garcia-Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., Dannaoui, E. (2007). Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59: 1076-1083 [Abstract] [Full Text]  
  • Wiederhold, N. P., Najvar, L. K., Bocanegra, R., Molina, D., Olivo, M., Graybill, J. R. (2007). In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera. Antimicrob. Agents Chemother. 51: 1616-1620 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Cota, J., Carden, M., Graybill, J. R., Najvar, L. K., Burgess, D. S., Wiederhold, N. P. (2006). In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility. Antimicrob. Agents Chemother. 50: 3926-3928 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). Global Surveillance of In Vitro Activity of Micafungin against Candida: a Comparison with Caspofungin by CLSI-Recommended Methods.. J. Clin. Microbiol. 44: 3533-3538 [Abstract] [Full Text]  
  • Morris, M. I., Villmann, M. (2006). Echinocandins in the management of invasive fungal infections, part 1.. Am J Health Syst Pharm 63: 1693-1703 [Abstract] [Full Text]  
  • Bennett, J. E. (2006). Echinocandins for Candidemia in Adults without Neutropenia. NEJM 355: 1154-1159 [Full Text]  
  • Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., Scalise, G. (2006). Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis.. Antimicrob. Agents Chemother. 50: 2719-2727 [Abstract] [Full Text]  
  • Katiyar, S., Pfaller, M., Edlind, T. (2006). Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility.. Antimicrob. Agents Chemother. 50: 2892-2894 [Abstract] [Full Text]  
  • Hakki, M., Staab, J. F., Marr, K. A. (2006). Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy.. Antimicrob. Agents Chemother. 50: 2522-2524 [Abstract] [Full Text]  
  • Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., Cannon, R. D. (2006). Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility.. Antimicrob. Agents Chemother. 50: 1148-1155 [Abstract] [Full Text]  
  • Clemons, K. V., Espiritu, M., Parmar, R., Stevens, D. A. (2006). Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.. Antimicrob. Agents Chemother. 50: 1293-1297 [Abstract] [Full Text]  
  • Laverdiere, M., Lalonde, R. G., Baril, J.-G., Sheppard, D. C., Park, S., Perlin, D. S. (2006). Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57: 705-708 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2006). In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance.. J. Clin. Microbiol. 44: 760-763 [Abstract] [Full Text]  
  • Chamilos, G., Lewis, R. E., Kontoyiannis, D. P. (2006). Inhibition of Candida parapsilosis Mitochondrial Respiratory Pathways Enhances Susceptibility to Caspofungin. Antimicrob. Agents Chemother. 50: 744-747 [Abstract] [Full Text]  
  • Kartsonis, N., Killar, J., Mixson, L., Hoe, C.-M., Sable, C., Bartizal, K., Motyl, M. (2005). Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome. Antimicrob. Agents Chemother. 49: 3616-3623 [Abstract] [Full Text]  
  • Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S. A., Kurtz, M., Teppler, H., Douglas, C. M., Perlin, D. S. (2005). Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 49: 3264-3273 [Abstract] [Full Text]  
  • Oliveira, E. R., Fothergill, A. W., Kirkpatrick, W. R., Coco, B. J., Patterson, T. F., Redding, S. W. (2005). In Vitro Interaction of Posaconazole and Caspofungin against Clinical Isolates of Candida glabrata. Antimicrob. Agents Chemother. 49: 3544-3545 [Abstract] [Full Text]  
  • Messer, S. A., Kirby, J. T., Sader, H. S., Fritsche, T. R., Jones, R. N. (2004). Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J Antimicrob Chemother 54: 1051-1056 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hernandez, S.
Right arrow Articles by Graybill, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hernandez, S.
Right arrow Articles by Graybill, J. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»